- Home
- RBOT vs MDXH Comparison
RBOT vs MDXH Comparison
Compare RBOT & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RBOT
- MDXH
- Stock Information
- Founded
- RBOT 2014
- MDXH 2003
- Country
- RBOT United States
- MDXH Belgium
- Employees
- RBOT N/A
- MDXH N/A
- Industry
- RBOT Medical Specialities
- MDXH
- Sector
- RBOT Health Care
- MDXH
- Exchange
- RBOT Nasdaq
- MDXH Nasdaq
- Market Cap
- RBOT 61.4M
- MDXH 141.1M
- IPO Year
- RBOT N/A
- MDXH 2021
- Fundamental
- Price
- RBOT $5.85
- MDXH $3.66
- Analyst Decision
- RBOT Hold
- MDXH Buy
- Analyst Count
- RBOT 1
- MDXH 1
- Target Price
- RBOT $7.00
- MDXH $6.00
- AVG Volume (30 Days)
- RBOT 39.2K
- MDXH 176.2K
- Earning Date
- RBOT 11-11-2025
- MDXH 11-05-2025
- Dividend Yield
- RBOT N/A
- MDXH N/A
- EPS Growth
- RBOT N/A
- MDXH N/A
- EPS
- RBOT N/A
- MDXH N/A
- Revenue
- RBOT N/A
- MDXH $98,953,000.00
- Revenue This Year
- RBOT N/A
- MDXH $24.77
- Revenue Next Year
- RBOT N/A
- MDXH $22.21
- P/E Ratio
- RBOT N/A
- MDXH N/A
- Revenue Growth
- RBOT N/A
- MDXH 22.56
- 52 Week Low
- RBOT $5.00
- MDXH $1.35
- 52 Week High
- RBOT $19.00
- MDXH $3.91
- Technical
- Relative Strength Index (RSI)
- RBOT 38.77
- MDXH 65.69
- Support Level
- RBOT $5.58
- MDXH $3.46
- Resistance Level
- RBOT $5.99
- MDXH $3.91
- Average True Range (ATR)
- RBOT 0.41
- MDXH 0.18
- MACD
- RBOT 0.06
- MDXH -0.01
- Stochastic Oscillator
- RBOT 19.74
- MDXH 45.65
About RBOT Vicarious Surgical Inc.
Vicarious Surgical Inc designs a surgical robot that enables surgeons to perform minimally invasive surgery with 3D visualization and accurate control. Its Vicarious Surgical Robotic System is designed with a focus on abdominal access and visualization through a single port.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.